Captopril inhibits glioma cell invasion in vitro: involvement of matrix metalloproteinases
- PMID: 8572589
Captopril inhibits glioma cell invasion in vitro: involvement of matrix metalloproteinases
Abstract
We investigated the effects of captopril on the activity of matrix metalloproteinases (MMPs) secreted by T98G glioma cells and their invasiveness in vitro. On gelatin zymography, captopril inhibited gelatinolytic activities in the culture media of T98G cells. This inhibitory effect was reversed by the presence of excess zinc. In an in vitro invasion assay, invasion into the reconstituted basement membrane (Matrigel) by T98G glioma cells was inhibited by captopril in a dose-dependent manner. This inhibitory effect was also reversed by the addition of zinc to the culture media. However, at the effective concentration of captopril for the prevention of tumor cell invasion it did not inhibit the motility, adhesion to Matrigel or proliferation of T98G cells. These findings suggest that captopril inhibits the invasiveness of T98G glioma cells due to its MMP inhibitory activity, chelating zinc ions at the active center of MMPs.
Similar articles
-
Hyaluronic acid facilitates glioma cell invasion in vitro.Anticancer Res. 1996 Sep-Oct;16(5A):2917-22. Anticancer Res. 1996. PMID: 8917407
-
Inhibition of matrix metalloproteinase activity and growth of gastric adenocarcinoma cells by an angiotensin converting enzyme inhibitor in in vitro and murine models.Eur J Surg Oncol. 2005 Nov;31(9):1042-50. doi: 10.1016/j.ejso.2005.04.003. Epub 2005 Jul 1. Eur J Surg Oncol. 2005. PMID: 15993560
-
Purification of motility factor (GMF) from human malignant glioma cells and its biological significance in tumor invasion.Biochem Biophys Res Commun. 1993 Jun 15;193(2):518-25. doi: 10.1006/bbrc.1993.1654. Biochem Biophys Res Commun. 1993. PMID: 8390244
-
Matrix metalloproteinase-2 and -9 in glioblastoma: a trio of old drugs-captopril, disulfiram and nelfinavir-are inhibitors with potential as adjunctive treatments in glioblastoma.Arch Med Res. 2012 Apr;43(3):243-7. doi: 10.1016/j.arcmed.2012.04.005. Epub 2012 May 5. Arch Med Res. 2012. PMID: 22564423 Review.
-
Galanin suppresses proliferation of human U251 and T98G glioma cells via its subtype 1 receptor.Biol Chem. 2017 Sep 26;398(10):1127-1139. doi: 10.1515/hsz-2016-0320. Biol Chem. 2017. PMID: 28525358 Review.
Cited by
-
Multi-agent cytostatic treatment of 'low-grade' gliomas.Curr Oncol Rep. 2000 Sep;2(5):454-62. doi: 10.1007/s11912-000-0066-0. Curr Oncol Rep. 2000. PMID: 11122878 Review.
-
Glioblastoma and the search for non-hypothesis driven combination therapeutics in academia.Front Oncol. 2023 Jan 17;12:1075559. doi: 10.3389/fonc.2022.1075559. eCollection 2022. Front Oncol. 2023. PMID: 36733367 Free PMC article. Review.
-
CUSP9* treatment protocol for recurrent glioblastoma: aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, ritonavir, sertraline augmenting continuous low dose temozolomide.Oncotarget. 2014 Sep 30;5(18):8052-82. doi: 10.18632/oncotarget.2408. Oncotarget. 2014. PMID: 25211298 Free PMC article.
-
The expression and activation of matrix metalloproteinase-2 in rat brain after implantation of C6 rat glioma cells.J Neurooncol. 2000;46(2):105-14. doi: 10.1023/a:1006387600909. J Neurooncol. 2000. PMID: 10894363
-
Do statins, ACE inhibitors or sartans improve outcome in primary glioblastoma?J Neurooncol. 2018 May;138(1):163-171. doi: 10.1007/s11060-018-2786-8. Epub 2018 Feb 8. J Neurooncol. 2018. PMID: 29423540 Clinical Trial.